Big pharma bets big on kidneys. AstraZeneca has signed a deal worth up to $1.77 billion with China's CSPC Pharmaceutical Group to discover and develop new treatments for kidney disease. The partnership gives AstraZeneca exclusive global rights to promising small nucleic acid drug candidates, with CSPC set to receive an upfront $30 million plus milestone payments.
Big pharma bets big on kidneys. AstraZeneca has inked a deal worth up to $1.77 billion with China's CSPC Pharmaceutical Group to discover and develop experimental medicines targeting kidney diseases. While the specific conditions haven't been disclosed, the partnership signals a major push into a space affecting hundreds of millions of people globally.
Under the agreement, AstraZeneca gains the option to secure exclusive rights to develop, manufacture, and commercialize one preclinical small nucleic acid drug candidate worldwide, and a second candidate outside of China. This isn't the first time the two companies have teamed up — they previously collaborated on obesity and weight-related therapies.
By the Numbers:
Why it matters: Chronic kidney disease is a slow-moving but massive global health burden with limited treatment options. This deal reflects growing pharmaceutical interest in nucleic acid-based therapies and cross-border partnerships to accelerate drug discovery in underserved disease areas.
